The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Functionalization of Platinum Complexes for Biomedical Applications
Abstract
Platinum-based anticancer drugs are the mainstay of chemotherapy regimens in clinic. Nevertheless, the efficacy of platinum drugs is badly affected by serious systemic toxicities and drug resistance, and the pharmacokinetics of most platinum drugs is largely unknown. In recent years, a keen interest in functionalizing platinum complexes with bioactive molecules, targeting groups, photosensitizers, fluorophores, or nanomaterials has been sparked among chemical and biomedical researchers. The motivation for functionalization comes from some of the following demands: to improve the tumor selectivity or minimize the systemic toxicity of the drugs, to enhance the cellular accumulation of the drugs, to overcome the tumor resistance to the drugs, to visualize the drug molecules in vitro or in vivo, to achieve a synergistic anticancer effect between different therapeutic modalities, or to add extra functionality to the drugs. In this Account, we present different strategies being used for functionalizing platinum complexes, including conjugation with bisphosphonates, peptides, receptor-specific ligands, polymers, nanoparticles, magnetic resonance imaging contrast agents, metal chelators, or photosensitizers. Among them, bisphosphonates, peptides, and receptor-specific ligands are used for actively targeted drug delivery, polymers and nanoparticles are for passively targeted drug delivery, magnetic resonance imaging contrast agents are for theranostic purposes, metal chelators are for the treatment or prevention of Alzheimer's disease (AD), and photosensitizers are for photodynamic therapy of cancers. The rationales behind these designs are explained and justified at the molecular or cellular level, associating with the requirements for diagnosis, therapy, and visualization of biological processes. To illustrate the wide range of opportunities and challenges that are emerging in this realm, representative examples of targeted drug delivery systems, anticancer conjugates, anticancer theranostic agents, and anti-AD compounds relevant to functionalized platinum complexes are provided. All the examples exhibit new potential of platinum complexes for future applications in biomedical areas. The emphases of this Account are placed on the functionalization for targeted drug delivery and theranostic agents. In the end, a general assessment of various strategies has been made according to their major shortcomings and defects. The original information in this Account comes entirely from literature appearing since 2010.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Effect of Nanoparticle Size, Shape, and Surface Chemistry on Biological Systems
Albanese, A., Tang, P. S., & Chan, W. C. W. (2012) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071811-150124 · Cited by 3,633
Fang, J., Nakamura, H., & Maeda, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.04.009 · Cited by 3,559
Effect of Surface Properties on Nanoparticle–Cell Interactions
Verma, A., & Stellacci, F. (2010) · Small · doi:10.1002/smll.200901158 · Cited by 2,619
Gold Nanoparticles for Biology and Medicine
Giljohann, D. A., Seferos, D. S., Daniel, W. L., Massich, M. D., Patel, P. C., & Mirkin, C. A. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200904359 · Cited by 2,356
Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization
Celli, J. P., Spring, B. Q., Rizvi, I., Evans, C. L., Samkoe, K. S., Verma, S., Pogue, B. W., & Hasan, T. (2010) · Chemical Reviews · doi:10.1021/cr900300p · Cited by 2,324
The status of platinum anticancer drugs in the clinic and in clinical trials
Wheate, N. J., Walker, S., Craig, G. E., & Oun, R. (2010) · Dalton Transactions · doi:10.1039/c0dt00292e · Cited by 1,634
Synthesis, Functionalization, and Biomedical Applications of Multifunctional Magnetic Nanoparticles
Hao, R., Xing, R., Xu, Z., Hou, Y., Gao, S., & Sun, S. (2010) · Advanced Materials · doi:10.1002/adma.201000260 · Cited by 1,372
Gold Nanoparticles for the Improved Anticancer Drug Delivery of the Active Component of Oxaliplatin
Brown, S. D., Nativo, P., Smith, J.-A., Stirling, D., Edwards, P. R., Venugopal, B., Flint, D. J., Plumb, J. A., Graham, D., & Wheate, N. J. (2010) · Journal of the American Chemical Society · doi:10.1021/ja908117a · Cited by 865
Targeting and delivery of platinum-based anticancer drugs
Wang, X., & Guo, Z. (2013) · Chem. Soc. Rev. · doi:10.1039/c2cs35259a · Cited by 684
Self-citationDai, Y., Xiao, H., Liu, J., Yuan, Q., Ma, P., Yang, D., Li, C., Cheng, Z., Hou, Z., Yang, P., et al. (2013) · Journal of the American Chemical Society · doi:10.1021/ja410028q · Cited by 529
Cited by
Encyclopedia of Inorganic and Bioinorganic Chemistry
(2011) · Wiley eBooks · doi:10.1002/9781119951438 · Cited by 1,585
Platinum-based drugs for cancer therapy and anti-tumor strategies
Zhang, C., Xu, C., Gao, X., & Yao, Q. (2022) · Theranostics · doi:10.7150/thno.69424 · Cited by 1,018
Zhou, J., Yu, G., & Huang, F. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00898d · Cited by 677
Ma, P., Xiao, H., Yu, C., Liu, J., Cheng, Z., Song, H., Zhang, X., Li, C., Wang, J., Gu, Z., et al. (2017) · Nano Letters · doi:10.1021/acs.nanolett.6b04269 · Cited by 649
Stimuli-Responsive Therapeutic Metallodrugs
Wang, X., Wang, X., Jin, S., Muhammad, N., & Guo, Z. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00209 · Cited by 649
Self-citationDrug self-delivery systems for cancer therapy
Qin, S.-Y., Zhang, A.-Q., Cheng, S.-X., Rong, L., & Zhang, X.-Z. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2016.10.016 · Cited by 532
Advances in Toxicological Research of the Anticancer Drug Cisplatin
Qi, L., Luo, Q., Zhang, Y., Jia, F., Zhao, Y., & Wang, F. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00204 · Cited by 440
Update on metal N-heterocyclic carbene complexes as potential anti-tumor metallodrugs
Liu, W., & Gust, R. (2016) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2016.09.004 · Cited by 351
Yang, K., Yu, G., Yang, Z., Yue, L., Zhang, X., Sun, C., Wei, J., Rao, L., Chen, X., & Wang, R. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202103721 · Cited by 255
NIR‐II Emissive Ru(II) Metallacycle Assisting Fluorescence Imaging and Cancer Therapy
Fan, Y., Li, C., Bai, S., Ma, X., Yang, J., Guan, X., & Sun, Y. (2022) · Small · doi:10.1002/smll.202201625 · Cited by 51
Metadata
- Authors
- Wang, X., Wang, X., & Guo, Z.
- Venue
- Accounts of Chemical Research
- Publisher
- American Chemical Society (ACS)
- Published
- 2015-08-06
- Volume
- 48
- Issue
- 9
- Pages
- 2622-2631
- ISSN
- 0001-4842 (ISSN-L)
- 1520-4898
- OpenAlex
- W2413990098
- Cited by
- 268
- References
- 63
- FWCI
- 11.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.